Sustained efficacy of agomelatine 10 mg, 25 mg, and 25-50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months

European Neuropsychopharmacology

Volumn 26, Issue 2, 2016, Pages 378-389

  Kennedy, Sidney H ^a   Avedisova, Alla ^b   Belaïdi, Carole ^c   Picarel Blanchot, Françoise ^c   de Bodinat, Christian ^c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b Serbsky State Scientific Center of Social and Forensic Psychiatry   (Russian Federation)

^c IRIS Institut de Recherches Internationales Servier   (France)

Author keywords

Agomelatine; Depression; Dose regimen; Long term; Placebo

Indexed keywords

AGOMELATINE; PLACEBO; ACETAMIDE DERIVATIVE; ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; BRONCHITIS; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SHEEHAN DISABILITY SCALE; SOMNOLENCE; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; ANALYSIS OF VARIANCE; CLINICAL TRIAL; DEPRESSIVE DISORDER, MAJOR; FOLLOW UP; INTERNATIONAL COOPERATION; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; RETROSPECTIVE STUDY; TIME FACTOR; YOUNG ADULT;

ACETAMIDES; ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84958108767     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.09.006     Document Type: Article

References (27)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, Washington DC. 4th edn.
2. Asnis G.M., Bose A., Gommoll C.P., Chen C., Greenberg W.M. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 2013, 74:242-248.
3. Bech P., Wilson P., Wessel T., Lunde M., Fava M. A validation analysis of two self-reported HAM-D6 versions. Acta Psychiatr. Scand. 2009, 119:298-303.
4. Davidson J.R. Major depressive disorder treatment guidelines in America and Europe. J. Clin. Psychiatry 2010, 71(Suppl E1):e04.
5. de Bodinat C., Guardiola-Lemaitre B., Mocaer E., Renard P., Munoz C., Millan M.J. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat. Rev. Drug Discov. 2010, 9:628-642.
6. Demyttenaere K., Corruble E., Hale A., Quera-Salva M.A., Picarel-Blanchot F., Kasper S. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. CNS Spectr. 2013, 18:163-170.
7. Fava G.A., Ruini C., Belaise C. The concept of recovery in major depression. Psychol. Med. 2007, 37:307-317.
8. Greer T.L., Kurian B.T., Trivedi M.H. Defining and measuring functional recovery from depression. CNS Drugs 2010, 24:267-284.
9. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare publication ADM 76-338 1976, 217-222. National Institute of Mental Health, Rockville MD.
10. Heun R., Ahokas A., Boyer P., Giménez-Montesinos N., Pontes-Soares F., Olivier V., Agomelatine Study Group The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo controlled trial. J. Clin. Psychiatry 2013, 74:587-594.
11. Hickie I.B., Rogers N.L. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 2011, 378:621-631.
12. Judd L.L., Paulus M.J., Schettler P.J., Akiskal H.S., Endicott J., Leon A.C., Maser J.D., Mueller T., Solomon D.A., Keller M.B. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?. Am. J. Psychiatry 2000, 157:1501-1504.
13. Kennedy S.H., Avedisova A., Gimenez-Montesinos N., Belaidi C., de Bodinat C. A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder. Eur. Neuropsychopharmacol. 2014, 24:553-563.
14. Kennedy S.H., Rizvi S.J. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs 2010, 24:479-499.
15. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., Rush A.J., Walters E.E., Wang P.S. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105.
16. Lam R.W., Endicott J., Hsu M.A., Fayyad R., Guico-Pabia C., Boucher M. Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine. Int. Clin. Psychopharmacol. 2014, 29:239-251.
17. Langlieb A.M., Guico-Pabia C.J. Beyond symptomatic improvement:assessing real-world outcomes in patients with major depressive disorder. Prim. Care Companion J. Clin. Psychiatry 2010, 12.
18. Mancini M., Sheehan D.V., Demyttenaere K., Amore M., Deberdt W., Quail D., Sagman D. Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies. Int. Clin. Psychopharmacol. 2012, 27:298-309.
19. Montgomery S.A., Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int. Clin. Psychopharmacol. 2007, 22:283-291.
20. Montgomery S.A., Nielsen R.Z., L.H.Poulsen, Haggstrom L. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum. Psychopharmacol. 2014, 29:470-482.
21. Sheehan D.V., Harnett-Sheehan K., Raj B.A. The measurement of disability. Int. Clin. Psychopharmacol. 1996, 11(Suppl 3):S89-S95.
22. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl 20):S22-S33.
23. Sheehan K.H., Sheehan D.V. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int. Clin. Psychopharmacol. 2008, 23:70-83.
24. Taylor D., Sparshatt A., Varma S., Olofinjana O. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ 2014, 348:g1888.
25. Troisi A. Mental health and well-being: clinical applications of Darwinian psychiatry. Applied Evolutionary Psychology 2012, 276-289. Oxforf University Press, New York. S. Craig Roberts (Ed.).
26. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983, 67:361-370.
27. Zimmerman M., McGlinchey J.B., Posternak M.A., Friedman M., Attiullah N., Boerescu D. How should remission from depression be defined? The depressed patient's perspective. Am. J. Psychiatry 2006, 163:148-150.